CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

BeOne Medicines Publishes Clinical Trial Portfolio Presentation

By Public Technologies
  • BeOne Medicines published its Q3 2026 clinical trials portfolio presentation.
  • Sonrotoclax holds U.S. approval for relapsed or refractory mantle cell lymphoma; an EU submission has been accepted.
  • Phase 3 trials of sonrotoclax in relapsed or refractory blood cancers remain enrolling.
  • Tacabrutideg’s Phase 3 trial against pirtobrutinib in relapsed or refractory CLL/SLL is enrolling 500 patients.
  • New pivotal programs include B7-H4 ADC in first-line ovarian cancer maintenance and GPC3-targeted therapy in second-line or later liver cancer.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BeOne Medicines AG published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk